

1 / 21




FIG. 1A

2 / 21




FIG. 1B




FIG. 1C




FIG. 1D

3 / 21




FIG. 2A

4 / 21




FIG. 2B

5 / 21




FIG. 3 -

6 / 21




FIG. 4A




FIG. 4B

7 / 21




FIG. 5

8 / 21




FIG. 6A




FIG. 6B




FIG. 6C



9 / 21




FIG. 6D




FIG. 6E




FIG. 6F

10 / 21




FIG. 7




FIG. 8

12 / 21




FIG. 9

13 / 21




FIG. 10

14 / 21




FIG. 11

15 / 21




**A****B**

FIG. 12A-B

16/21


C



CT

RXR $\alpha$ <sup>ep-/-</sup>

D



CT

RXR $\alpha$ <sup>ep-/-</sup>

FIG. 12C-D



17 / 21




FIG. 13A-B

18 / 21

Histological analysis of paraffin sections (5 µm-thick) of biopsies of 8-16 mm tumors from CT and RXRα<sup>ap/-</sup> mice, 25 and 30 weeks after the start of the DMBA/TPA treatment

Mouse	Weeks After DMBA/TPA	Number of papillomas	Papillomas exhibiting						
			In situ carcinoma	FC	SCC (I)	SCC (II)	SCC (III)	SCC (IV)	SpCC BCC
CT	25	20	1/20 (5%)	0/20	0/20	0/20	0/20	0/20	0/20
	30	31	1/31 (~3%)	5/31 (~16%)	0/31	0/31	0/31	0/31	0/31
RXRα <sup>ap/-</sup>	25	20	2/20 (10%)	8/20 (40%)	0/20	0/20	0/20	0/20	0/20
	30	35	1/35 (~3%)	7/35 (20%)	3/35 (~9%)	3/35 (~9%)	1/35 (~3%)	2/35 (~6%)	3/35 (~9%)

FC, focal carcinoma; SCC, squamous cell carcinoma; SpCC, spindle cell carcinoma; BCC, basal cell carcinoma

FIG. 13C

19 / 21




FIG. 14A-B

20 / 21




FIG. 14C

21 / 21




FIG. 15